¹**Title Page**

²*Schistosoma mansoni* infection alters the host pre-vaccination environment resulting in blunted Hepatitis ³B vaccination immune responses.

 $\overline{4}$

- ¹² Pediatric Infectious Diseases, Stanford University School of Medicine, Palo Alto, CA, USA
- ¹³ Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco,
- 31 USA
- ¹⁴ Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands
- ¹⁵ Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands
- ¹⁶ IAVI, New York, New York, USA, and Nairobi, Kenya
-
- 36 Correspondence should be addressed to Elias K. Haddad, Ph.D., Division of Infectious Diseases and HIV
- 37 Medicine, Department of Medicine, Drexel University College of Medicine, 245 N. 15th Street, MS-461,
- ³⁸Philadelphia, Pennsylvania, 19102, USA. Telephone: E-mail: ee336@drexel.edu
-

⁴⁰**Conflicts of Interest**

- 41 The authors have declared that no conflict of interest exists.
-

⁴³**Short Title**

44 Schistosomiasis and Hepatitis B vaccination responses

-
-
- 47
-
- 49
- 50
- 51

⁵²**Abstract**

53 The impact of endemic infections on protective immunity is critical to inform vaccination strategies. In 54 this study, we assessed the influence of *Schistosoma mansoni* infection on host responses in a Ugandan ⁵⁵fishing cohort given a Hepatitis B (HepB) vaccine. Concentrations of schistosome-specific circulating 56 anodic antigen (CAA) pre-vaccination showed a significant bimodal distribution associated with HepB 57 titers, which were lower in individuals with high CAA. We established that participants with high CAA 58 had significantly lower frequencies of circulating T follicular helper (cTfh) subpopulations pre- and post-59 vaccination and higher regulatory T cells (Tregs) post-vaccination. Polarization towards higher ⁶⁰frequencies of Tregs: cTfh cells can be mediated by changes in the cytokine environment favoring Treg 61 differentiation. In fact, we observed higher levels of CCL17 and soluble IL-2R pre-vaccination (important 62 for Treg recruitment and development), in individuals with high CAA that negatively associated with ⁶³HepB titers. Additionally, alterations in pre-vaccination monocyte function correlated with HepB titers, ⁶⁴and changes in innate-related cytokines/chemokine production were associated with increasing CAA ⁶⁵concentration. We report, that by influencing the immune landscape, schistosomiasis has the potential to ⁶⁶modulate immune responses to HepB vaccination. These findings highlight multiple *Schistosoma*-related 67 immune associations that could explain abrogated vaccine responses in communities with endemic 68 infections.

69

⁷⁰**Author Summary**

71 Schistosomiasis drives host immune responses for optimal pathogen survival, potentially altering host 72 responses to vaccine-related antigen. Chronic schistosomiasis and co-infection with hepatotropic viruses ⁷³are common in countries where schistosomiasis is endemic. We explored the impact of *Schistosoma* ⁷⁴*mansoni* (*S. mansoni*) infection on Hepatitis B (HepB) vaccination of individuals from a fishing 75 community in Uganda. We demonstrate that high schistosome-specific antigen (circulating anodic 76 antigen, CAA) concentration pre-vaccination, is associated with lower HepB antibody titers post-

101

¹⁰²**Introduction**

103 While vaccines have reshaped public health and saved millions of lives from the threat of many 104 infectious diseases (1), inadequate immune responses to vaccination remain a challenge, with a range of 105 contributary causes, such as chronic illnesses, including those stemming from helminth worm infections ¹⁰⁶(2-4). Schistosomiasis is a neglected tropical disease (NTD) caused by parasitic flatworms from three ¹⁰⁷main *Schistosoma* spp. that often develops into a chronic infection in endemic populations, with 90% of 108 all infections found in sub-Saharan Africa. An estimated four million people in Uganda are infected 109 with *S. mansoni* and about 55% of the population is at risk of infection (5, 6). Currently, treatment with ¹¹⁰Praziquantel (PZQ) is the only safe and effective protocol against infection with *Schistosoma* spp. and 111 control of Schistosomiasis in endemic regions involves periodic administration of PZQ to communities 112 (7) .

¹¹³Chronic schistosomiasis with hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection is 114 common in countries where schistosomiasis is endemic. There is also evidence that *S. mansoni* co-115 infection with hepatotropic viruses may exacerbate resultant hepatic pathology (8). In Uganda, more than 116 1.4 million adults are chronically infected with hepatotropic viruses, and the prevalence of HBV is 117 approximately 8.5% (9, 10) with an increased incidence in the Lake Victoria fishing communities (11). ¹¹⁸While vaccination against Hepatitis B (HepB) is highly effective in the prevention of infection, there are 119 still $\sim 800,000$ deaths attributable to acute and chronic HepB disease annually (12). Furthermore, 5-10% 120 of individuals do not mount an effective antibody response to HepB vaccination (13). There is a need for 121 improved understanding of the immunological responses during vaccination to ensure effective responses 122 in compromised host immune systems.

¹²³*Schistosoma* spp. induces strong host T helper 2 (Th2) responses, but also go on to induce 124 regulatory T cell (Treg) responses which in turn curbs T helper immunity (14, 15). Specifically, the 125 chronic phase develops due to continual exposure to the soluble egg antigen (SEA) of schistosome eggs

126 in the host tissues, driving immune-pathology and progressing to granuloma formation, characterized by 127 an increase in lymphocytes (CD4⁺ T cells) producing T-helper-2 (Th2) cytokines such as interleukins (IL) ¹²⁸-4, -5, and -13. This heightened Th2 response becomes suppressed over time to induce tolerance, which is 129 the major influence on worm survival in the host (16, 17). Upregulation of these responses could 130 potentially inhibit the T helper responses induced by vaccination, such as T follicular helper (Tfh) 131 responses which are critical for B cell help (18, 19), and foster conditions that cause alterations of ¹³²vaccine-induced antibody responses. Studies showing the effects of *Schistosoma* infection on the ¹³³modulation of immune responsiveness to concomitant diseases and immunization are not without 134 controversy; however, the consensus is this infection can diminish or alter immune responses to non-135 schistosome antigens. These responses may lead to either beneficial or detrimental outcomes for the host. 136 In the case of vaccine responses, animal models of malaria (20), bacteria (21) and HepB (22) show 137 reduced protective effects; and human vaccination studies have shown lower levels of vaccine-specific ¹³⁸antibody in *Schistosoma*-infected children (23, 24), and in HepB vaccination of adults (25, 26). However, 139 the impact of *S. mansoni* infection and worm burden on host immune response to vaccines, and to HepB 140 vaccination, is still poorly understood; and the underlying actions of immune mediators affecting these 141 responses need to be further elucidated to identify strategies to optimize vaccination effectiveness.

142 Detection of CAA (Circulating Anodic Antigen, a worm antigen regurgitated into the 143 bloodstream of the host) in serum indicates an ongoing infection, implying the presence of living ¹⁴⁴*Schistosoma* worms. CAA is produced at a steady level and although worm pairs do produce eggs, worms 145 do not multiply and there is a direct association of CAA serum level with worm burden. It was estimated 146 that an amount of 1-10 pg/mL blood corresponds to a single healthy worm pair $(27, 28)$. In this study, we 147 characterized soluble and cellular immune factors at pre- and post-immunization timepoints with a HepB 148 vaccine in PZQ-treated individuals with high and low CAA and explored mechanisms which may be 149 responsible for a blunted vaccine response in individuals with high CAA and likely a high worm burden. ¹⁵⁰We demonstrated that *S. mansoni* infection is associated with significantly lower HepB vaccine-specific 151 antibody responses and showed these responses coincided with alterations in cytokines and chemokines

152 that are important for Tfh and Treg cell recruitment and function. We propose that a high CAA ¹⁵³concentration due to a high *S. mansoni* worm burden pre-vaccination, can reshape the baseline 154 environment, and modulate the response to vaccines.

-
- ¹⁵⁶**Results**

¹⁵⁷**Pre-vaccination** *S. mansoni* **infection negatively impacts Hepatitis B antibody titers post-vaccination**

158 Seventy-five participants for the present study were recruited in Uganda among fishing 159 communities on the northern shores of Lake Victoria, where schistosomiasis is endemic and various 160 samples were collected at multiple timepoints for subsequent study analyses (Fig 1, S1 Table). HepB 161 antibody titers (anti-HBs) were determined in the serum at D0, M7 (1 month post- $2nd$ boost) and M12 (6 162 months post-2nd boost) to look at levels pre-vaccine, as well as short-term and longer-term post-163 vaccination antibody responses after completion of the immunization series (Fig 1 and S1 Table). A ¹⁶⁴circulating anodic antigen (CAA) detection assay (29-32) was also determined pre-vaccination (D0) in the ¹⁶⁵serum of enrolled participants (Fig 1 and S1 Table). The presence of CAA indicates an ongoing *S.* ¹⁶⁶*mansoni* infection, with CAA concentration closely linked to worm burden (27, 28) and those found to be 167 infected were treated with PZQ at day 12 (D12) post-vaccination (Fig 1). The results show that CAA 168 values displayed a bimodal distribution. The cutoff separating the two modes was estimated by ¹⁶⁹maximum-likelihood which revealed that participants could be separated into those with a CAA 170 concentration of <36 pg/mL (low or no worm burden); and those with a CAA concentration of \geq 36 pg/mL 171 (higher worm burden) (Fig 2A). Importantly, CAA values from these two groups of participants were 172 significantly associated with HepB titers measured at month 7 (M7), where low CAA was associated with 173 a high titer, and high CAA with a low titer (log10 fold change (FC)= -0.43 , 95% confidence interval (CI) ¹⁷⁴[-0.053, -0.81]; P*=*0.028) (Fig 2B). The same trend between HepB titers and the two CAA groups 175 was observed after adjusting for age and sex $(log10FC = -0.38, 95\% \text{ CI } [0.059, -0.81]; P=0.089$.

176 In acknowledging the role *S. mansoni* infection and worm burden could play in the modulation of 177 host immunity, whether the individuals at the time of the study were uninfected or infected, and the level 178 of *S. mansoni* worm burden, is important in data interpretation. For this reason, individuals were further 179 stratified into three groups using methodology from the CAA assay that allowed detection of samples as 180 low as 3pg/mL: non-infected (no) (CAA <3 pg/mL), low CAA concentration (low) (CAA 3-100 pg/mL) 181 and high CAA concentration (high) (CAA >100 pg/mL) (S1 Table) (33). Association of these three 182 groups with vaccine responses indicated higher HepB titers in non-infected individuals, followed by those 183 with low CAA and high CAA (Fig 2C and 2D). Overall, these data show an association between CAA 184 concentration pre-vaccination and vaccine-specific responses, specifically that that a higher CAA 185 concentration and likely higher worm burden, can negatively influence post-vaccination antibody titers.

¹⁸⁷**Plasma cytokines/chemokines involved in lymphocyte migration and activation are significantly** ¹⁸⁸**higher in** *S. mansoni* **infection pre-vaccination and persist at month 12 post-vaccination**

189 To elucidate any patterns of cytokine/chemokine production between infected groups pre-190 vaccination and post-vaccination, plasma samples from non-infected and *S. mansoni*-infected individuals 191 were analyzed using multiplex cytokine/chemokine platform of more than 65 soluble factors. We 192 identified that pre-vaccination systemic levels of CCL17 (no vs. low P=0.002, no vs. high P<0.0001), 193 CCL19 (no vs. low P=0.004, no vs. high P<0.0001, low vs. high P=0.040), CXCL9 (no vs. low P=0.012, 194 no vs. high P<0.0001, low vs. high P=0.002) (Fig 3A- 3C, S2 Table), and several other cytokines and 195 chemokines implicated in lymphocyte recruitment and activation (S1A- S1F Fig, S2 Table), were 196 significantly higher in individuals with low and high CAA compared to non-infected at D0. Of interest, 197 the levels of CCL17 (no vs. high P=0.012), CCL19 (no vs. high P=0.040) and CXCL9 (no vs. high 198 P=0.004, low vs. high P=0.031) remained significantly elevated in individuals with high CAA at M12 199 post-vaccination (Fig 3A-3C, S2 Table). Furthermore, principal component analysis (PCA) analysis 200 shows that cytokine/chemokine levels pre-vaccination, cluster separately from post-vaccination time 201 points, suggesting an association between HepB vaccination and major changes in circulating

202 cytokines/chemokines that are sustained over time (up to 6 months after the last immunization, Fig 2D). ²⁰³The relationship between alterations in these cytokines/chemokines and the levels of HepB titers, was 204 evaluated to identify biomarkers associated with a stronger humoral response to vaccination. Pre-205 vaccination (t=-3.01, P=0.004) and M12 post-vaccination (t=-2.40, P=0.020) levels of CCL17 showed a 206 negative correlation with HepB titers at M12 (S2A and S2B Fig, S3 Table). While levels of soluble IL-2R ²⁰⁷(sIL-2R) were not different in *S. mansoni* infection compared to non-infected (S2C Fig and S2 Table), 208 sIL-2R levels pre-vaccination (t=-2.22, P=0.032) and M12 post-vaccination (t=-2.95, P=0.005) were also 209 negatively correlated with HepB titers at M12 (S2D and S2E Fig, S3 Table). These observations suggest a 210 high worm burden in *S. mansoni* infection could be associated with alterations of the host 211 cytokine/chemokine response to vaccination and implicate CCL17 and potentially sIL-2R, known to 212 attract both effector and regulatory T cells $(34-38)$.

213

214 **Frequencies of circulating T follicular helper cell populations are significantly lower pre-**²¹⁵**vaccination which is sustained post-vaccination in** *S. mansoni* **infection and coincides with higher** ²¹⁶**frequencies of regulatory T cells in individuals with high CAA concentration**

217 Cellular immunological changes influenced by the cytokine environment are key in modulating 218 effective vaccine-specific humoral responses. We assessed frequencies of circulating T follicular helper ²¹⁹(cTfh) populations (39), critically involved in providing B cell help in infection and vaccination (40-42), 220 from the PBMCs of non-infected and *S. mansoni*-infected individuals by flow cytometry (S3 Fig). 221 Frequencies of cTfh1 (low vs. high P=0.020) and cTfh2 cells (no vs. high P=0.012, low vs. high P=0.014) 222 pre-vaccination (Fig 4A and 4B, S4 Table), were significantly lower in individuals with high CAA; and 223 cTfh1 cells remained significantly lower at M7 (low vs. high P=0.031) and M12 (no vs. high P=0.030, 224 low vs. high P=0.004) post-vaccination (Fig 4A, S4 Table). While differences between non-infected and ²²⁵*S. mansoni*-infected groups for cTfh17 cells pre-vaccination did not reach statistical significance, they 226 were significantly lower in *S. mansoni*-infected individuals at M12 post-vaccination (no vs. low P= 0.024, 227 no vs. high P=0.006) (Fig 4C, S4 Table). Importantly, these alterations were specific to cTfh cells, as no

228 statistically significant changes between groups were observed at any of the time points for non-cTfh cells 229 (Fig 4D). By contrast, frequencies of CXCR5⁻ regulatory T cells (Tregs), that were similar between non-230 infected and *S. mansoni*-infected groups pre-vaccination, were significantly higher at M7 (no vs. high 231 P=0.039) and M12 (no vs. high P=0.047) post-vaccination in individuals with high CAA (Fig 4E, S4 232 Table). These results suggest that frequencies of cTfh cells, which are important for instructing B cells to 233 produce antibodies, are significantly altered in instances of high worm burden, and the concomitant 234 increase in Tregs supports the theory that worm burden could have an impact on the interplay between 235 these two subsets.

²³⁷**Antibody-secreting B cells are significantly lower in instances of high worm burden and is** ²³⁸**associated with Hepatitis B antibody titers at month 12**

239 Cellular changes were further examined in response to *S. mansoni* infection and HepB 240 vaccination by looking at the frequencies of activated B cells (ABC) and antigen-specific antibody-241 secreting B cells (ASC) (43) (S4 Fig). Frequencies of ABCs (no vs. high $P=0.048$) and IgG⁺ABCs (no vs. 242 high P=0.015) were found to be significantly higher pre-vaccination in individuals with high CAA, with 243 similar results at M7 (ABC, no vs. high P=0.039; IgG⁺ABCs, no vs. high P=0.032) and M12 (ABC, no vs. 244 high P=0.040; IgG⁺ ABCs, no vs. high P=0.033) post-vaccination (S5A and S5B Fig, S5 Table), indicative 245 of a hyperactivated inflammatory B cell response (41). Of importance and in sharp contrast, lower 246 frequencies of KI67⁺ASC (no vs. high P=0.040), IgG⁺ASC (no vs. high P=0.046), and IgA⁺ASC (no vs. 247 high P=0.029) populations were observed in individuals with high CAA at M12 post-vaccination (Fig 5A-248 5C). Furthermore, assessment of the correlation between ASCs and HepB titers showed a positive 249 correlation between IgA⁺ ASCs and HepB titers at M12 (t=2.10, P=0.041) (S5C Fig and S6 Table). These 250 results imply that an elevated worm burden can influence humoral immunity, including isotype during 251 vaccination, particularly by modulating changes in the B cell compartment resulting in a highly non-²⁵²specific inflammatory B cell response, and a reduction in the vaccine-specific B cell response.

²⁵⁴**Impact of** *S. mansoni* **infection on Ig isotypes**

²⁵⁵B cell isotype switching changes the effector functions of antibodies and improves the 256 effectiveness of the required response to infection or vaccination. Herein, B cell function was further 257 investigated in the context of Ig class-switching by treating PBMCs from non-infected and *S. mansoni*-258 infected individuals with the TLR9 ligand CpG-ODN 2006 and analyzing the culture supernatant for Ig ²⁵⁹antibodies using a multiplex bead assay. IgG4, known to be associated with *Schistosoma* reinfection (44), 260 was found to be the only subclass with significant differences between non-infected and *S. mansoni*-261 infected at pre-vaccination, and had the highest levels in the high worm burden group (no vs. high 262 P=0.002, low vs. high P=0.003) (Fig 6A). We observed similar trends for plasma IgE pre-vaccination (no 263 vs. high P=0.0008, low vs. high P=0.0001); in contrast to CpG-induced IgG4, higher levels were 264 sustained at M12 post-vaccination (no vs. high P=0.001, low vs. high P=0.002) (S6 Fig). Furthermore, a 265 Luminex-based serologic assay was also used to quantify pre-vaccination levels of Schistosoma-specific 266 antibody isotypes and subclasses in the serum of participants, and the mean florescence intensity (MFI) of 267 S. mansoni-specific IgG4 was found to be significantly associated with CAA concentration (P=0.0008), 268 with higher levels in individuals with high CAA compared to non-infected $(P=0.0003)$ and individuals 269 with low CAA ($P=0.021$) (Fig 6B). Post-vaccination, IgA levels in the supernatant of CPG-stimulated ²⁷⁰PBMCs were found to be significantly different between non-infected and *S. mansoni*-infected 271 individuals, where the lowest levels were observed in individuals with high CAA (no vs. high $P=0.031$) ²⁷²(Fig 6C). The development of antigen-specific soluble IgA is thought to be critically important in an 273 effective immune response to vaccination (45), and these results reveal that worm burden could influence 274 the host's ability to mount a specific antibody response.

275

276 Vaccine-Specific Memory CD4⁺ T cells positively correlate with Hepatitis B antibody titers

 277 The CD4⁺ T cell memory compartment houses both the cTfh and Treg populations, which 278 showed variations in their frequencies in instances of *Schistosoma* infection pre- and post-vaccination ²⁷⁹(Fig 4). To determine the impact of *S. mansoni* infection on HepB-specific memory T cells, PBMCs from

280 non-infected and *S. mansoni*-infected individuals at M7 were treated with a Hepatitis B long envelope 281 protein (HBV LEP) peptide, and CFSE cells analyzed by flow cytometry were identified as vaccine-282 specific. Vaccine-specific memory $CD4^+$ T and $CD8^+$ T cells were significantly higher after peptide 283 stimulation compared to control (DMSO), and lower frequencies of proliferating $CD4^+$ T cells, but not 284 CD8⁺ T cells were observed in *S. Mansoni*-infected individuals compared to non-infected (Fig 7A and 285 7B). Interestingly, and in assessing an association with HepB titers, a positive association was observed 286 between vaccine-specific memory $CD4^+$ T cells and HepB titers (t=1.85, P=0.073) (Fig 7C), with a 287 concurrent significant negative correlation between vaccine-specific memory $CD8⁺$ T cells and HepB 288 titers (t=-2.36, P=0.025) (Fig 7D). These results highlight how $CD4^+$ and $CD8^+$ memory T cells may play 289 separate and antagonistic roles in their contribution to vaccination responses during infection.

²⁹¹**Monocyte function is positively associated with effective Hepatitis B vaccine responses**

292 Our analysis has pointed to the importance of key cytokines/chemokines involved in innate 293 responses to infection that was detected pre-vaccination, and how they may play a crucial role in ²⁹⁴modulating the immune response post-vaccination in non-infected and *S. mansoni*-infected individuals 295 with various levels of worm burden. To additionally investigate the importance of innate responses, the 296 frequencies of monocyte populations were determined by flow cytometry of PBMCs from non-infected ²⁹⁷and *S. mansoni*-infected participants (S7 Fig), however no differences between CAA groups were 298 observed pre-vaccination for all three monocyte populations (S8A- S8C Fig), even though CD14⁺CD16⁻ 299 classical monocytes were found to negatively associate with HepB titers significantly at M7 (coef=-0.027, 300 P=0.017) (S8D Fig). To further elucidate the relationship between monocyte function and HepB vaccine 301 responses, THP-1 cells (a monocyte cell line) were used to carry out an antibody-dependent cellular 302 phagocytosis (ADCP) assay, and ADCP was found to positively correlate with HepB titers at M12 303 (P=0.0008) (Fig 8A), HepB surface antigen (HbsAg)-specific IgG1 titers (P=0.009) (Fig 8B), and binding 304 of HbsAg-specific antibodies to the cytotoxic Fc gamma receptor 3A (Fc γ R3A) (P=0.001) (Fig 8C), 305 indicating the importance of monocyte function in an effective humoral immune response to the Hepatitis

306 B vaccine. As we did not observe any associations between monocyte subsets and CAA concentration, 307 suggesting that monocyte frequency is not directly affected by *S. mansoni* infection, we thought it was ³⁰⁸important to further examine associations of innate immune function with CAA concentration by 309 exploring the induction of cytokine/chemokines.

³¹¹**Innate immune-related cytokines/chemokines are significantly lower pre-vaccination and day 12** ³¹²**post-vaccination in instances of high CAA concentration after TLR7/8 stimulation**

313 Toll-like receptors (TLRs) mediate innate immune responses to pathogen-associated molecules 314 (46). To investigate the importance of monocyte function in shaping the response to Hepatitis B 315 vaccination during *S. mansoni* infection, PBMCs from non-infected and *S. mansoni*-infected individuals 316 were stimulated with a viral toll-like receptor (TLR) 7/8 agonist- imidazoquinoline compound CLO97, 317 and the supernatant analyzed by multiplex bead assay for cytokines/chemokines after 18 hours of 318 stimulation. Levels of the CXC chemokine IFN- γ -inducible protein 10 (CXCL10; IP-10), which plays a 319 crucial role in activating innate immune cells, promoting dendritic cell (DC) maturation, and inducing 320 protective T cell responses (47, 48), were significantly lower in CLO97-treated supernatant from the high 321 CAA group pre-vaccination (low vs. high P=0.031) (Fig 9A, S7 Table). Furthermore, supernatant levels 322 of CCL19 (no vs. high P=0.009), CCL26 (no vs. high P=0.014), CCL27 (no vs. high P=0.007), IL-1 β (no 323 vs. high P=0.028), and IL-10 (no vs. high P=0.008, low vs. high P=0.053) were also significantly lower in 324 the high CAA group after treatment with CLO97 D12 post-vaccination (Fig 9B-9F, S7 Table). ³²⁵Collectively, these cytokines/chemokines play important roles in early immune responses to viral 326 infection and vaccination including modulation of inflammatory responses and adaptive cell recruitment, 327 activation, and regulation (49-53). These results indicate an association between *S. mansoni* infection and ³²⁸worm burden in the altering of the pre-vaccination, and early post-vaccination innate cytokine 329 environment.

³³¹**Discussion**

³³²Vaccination is an essential tool in controlling the spread of infectious diseases, but variations of ³³³host immune responses to vaccines across populations (endemic infections, pre-existing infections, 334 geography, biological sex, race/ethnicity) impact the generation of protective immune responses, and thus 335 how vaccines can be designed to treat populations are at greater risk for poor clinical outcomes. These 336 variations in vaccine responses, seen in communities with endemic diseases such as schistosomiasis, have 337 recently been the topic of intense investigation $(3, 4)$. We show that pre-vaccination worm burden 338 specifically influences levels of vaccine-specific antibody production. Individuals from a Ugandan fishing 339 community cohort were stratified into non-infected and *S. mansoni*-infected with low worm burden (low 340 CAA concentration), or high worm burden (high CAA concentration) (33). We show that the pre-341 vaccination CAA values aligned with groups categorized by low and high worm burden displayed a 342 bimodal distribution, and that increasing CAA concentration was negatively associated with vaccine-343 specific antibody levels. This association also served as the premise for further investigation to delineate 344 what molecules and cell populations were at play, and responsible for these changes in vaccine-related 345 immune responses post-vaccination.

346 The major strength of this study lies in this unique cohort, which allowed analysis of individuals 347 pre-vaccination and post-vaccination, with different concentrations of CAA and likely different levels of 348 worm burden from direct exposure, or no *S. mansoni* infection at all; and allowed us to comment 349 definitively on the impact of baseline *S. mansoni* infection on vaccine-induced responses, and more 350 specifically if these induced responses were affected by worm burden. Notably, CAA concentration 351 indicates an active infection and the presence of living worms, allowing for serum CAA concentration to 352 be directly associated with worm burden (27, 28). While egg count data was determined, they are ³⁵³approximately 50% sensitive when done on a single stool sample (54). Furthermore, as the worms 354 themselves do not multiply, egg count data only indicates worm pairs producing eggs and not quantitative 355 data on overall worm burden (55). Our analysis of vaccine-specific antibody titers, cytokines/chemokines, ³⁵⁶and immune and adaptive cellular responses also allowed us to identify the links between high *S. mansoni*

357 worm burden and lower HepB vaccine responses. While the outcomes of this present study were based ³⁵⁸solely on the influence of *S. Mansoni* infection on HepB vaccination, we believe the results have the 359 potential to direct other immunization programs in schistosomiasis-impacted communities where repeated 360 exposure is likely.

361 Our analysis showed induction of several proinflammatory molecules involved in lymphocyte 362 migration and activation, including CCL17 in individuals with high CAA pre-vaccination suggesting a 363 coordinated immune response in instances of high worm burden. Higher levels of CCL17 and sIL-2R 364 showed negative associations with HepB titers in cases of high worm burden, identifying these two 365 molecules as potential biomarkers for inefficient antibody development. CCL17 has been shown to play a 366 key role in recruiting CCR4-expressing T helper and regulatory cells during inflammation (34-36, 38). 367 Furthermore, Wirnsberger and colleagues specifically show that IL-4 induces the expression of CCL17 ³⁶⁸(56), and we observed higher levels of IL-4 in individuals with high CAA post-vaccination (data not 369 shown) suggesting IL-4 may be playing a role in driving and sustaining the CCL17 responses observed. ³⁷⁰While T helper 1 and 2 responses, are predominant in Schistosomiasis (14), these chronically skewed 371 environments have been known to be antagonistic to Tfh-B cell interactions that are important for 372 inducing antigen-specific antibody responses (18, 19, 40). Furthermore, alterations in innate immune 373 function in *Schistosoma* infection observed in our cohort, may potentially play a role in these shifts in 374 these cytokine levels; and previous models have also shown that elevation of T-helper cytokines in *S.* ³⁷⁵*mansoni* infection correlate specifically with lower vaccine-specific responses to immunization against ³⁷⁶*Mycobacterium bovis* (BCG) (21), HepB and tetanus toxoid (26).

377 Several Tfh cell subsets involved in antibody induction during infection and vaccination, 378 including cTfh cells in the periphery, play a key role the generation of high-affinity antibody-producing 379 plasma cells and memory B cells (39). We also now know that changes observed in cTfh profiles are 380 known to reflect the cytokine microenvironment, and specific cTfh subpopulations are known to drive B 381 cell class switching (57). We demonstrated that individuals with high CAA had lower cTfh1 and -2 cells 382 pre-vaccination, which was sustained post-vaccination for cTfh1 and cTfh17 cells in this group. More

383 specifically, a positive association between HepB-specific memory $CD4^+$ T cell responses and HepB-384 specific antibody production was observed. These data highlight the vital role of HepB-specific memory 385 CD4⁺ T helper cells in driving antibody responses, and that changes in this compartment directly 386 influences vaccine responses. In parallel, we also reported higher frequencies of in Foxp3⁺ Tregs in 387 individuals with high CAA post-vaccination, suggesting a polarization towards higher frequencies of ³⁸⁸Tregs. These data strongly suggest that in instances of high worm burden, robust regulatory responses can 389 be induced by key pro-Treg cytokines pre-vaccination, such as CCL17 (36, 37), and other cytokines such 390 as IL-2 which we also observe to be elevated pre-vaccination (S1E Fig), can inhibit Tfh responses (58). 391 We believe this environment at baseline can dictate varied changes to the T cell profile and kinetics post-392 vaccination and skew the ratio of Tregs: cTfh cells when there is a high worm burden. Interestingly, it has 393 also been shown that the spleen is a major source of Tregs in hepatosplenic schistosomiasis (59), and we 394 can hypothesize that higher frequencies of Tregs in this condition, could contribute to a diminished 395 vaccine-induced response.

396 In support of our findings, Yin et. al. recently reported that lower responders to HepB vaccination 397 had lower frequencies of cTfh cells and antibody-secreting plasmablasts (42); and Musaigwa and 398 colleagues describe that *S. mansoni* infection specifically induces cell death in bone marrow plasmablasts 399 and plasma cells (60). We show in addition to a lower frequency of cTfh cells in individuals with high ⁴⁰⁰CAA, a significant increase in activated B cells but a reduction in proliferating (antigen-specific) ASCs, 401 ASCs expressing IgG and IgA, and that IgA⁺ASCs positively correlate with HepB titers. In addition to 402 these data, we see a significant reduction in TLR9-induced IgA levels post-vaccination. In combination, 403 these results point to a direct role for high worm burden environments pre-vaccination in influencing 404 changes in the immune landscape polarizing it away from cTfh and B cell responses which would hamper 405 vaccine-specific antibody production post-vaccination. Induction of IgA is a significant and desirable aim 406 of vaccination for its advantageous role in mucosal responses and has been proven to be associated with 407 protection effects post-vaccination (45, 61). We have also previously shown that changes to the cytokine ⁴⁰⁸microenvironment, particularly hyperinflammation, drives sustained dysregulation of the Tfh-B cell

409 interaction and hence B cell function (40, 41). Together these results emphasize that for successful 410 vaccination, an overall efficient Tfh and B cell response is required.

⁴¹¹Innate responses play critical role in shaping the adaptive immune response to vaccines. We show 412 the importance of monocyte function in innate immune responses and desired vaccine responses to HepB. ⁴¹³While our analysis showed higher levels of several innate proinflammatory cytokines in the plasma of ⁴¹⁴individuals with high CAA, we did not observe an association between frequencies of monocyte 415 populations and *S. mansoni* infection. However, after stimulation with a viral TLR 7/8 ligand, we show 416 that the levels of induced cytokines varied with *S. mansoni* infection, evidenced by mixed responses pre-417 and 12 days post-vaccination. These findings give some indication on how pro-inflammatory innate ⁴¹⁸environments could direct the disruption of efficient vaccine-specific responses during *Schistosoma* 419 infection. Furthermore, these results suggest that innate cells are playing a distinctive functional role in 420 changing this early cytokine/chemokine microenvironment, which we know impacts overall adaptive ⁴²¹immunity. Specifically, induction of CXCL10 (IP-10), which plays a crucial role in the activation and 422 recruitment of leukocytes and monocytes, promoting DC maturation and inducing protective T cell 423 responses (47, 48), was decreased in individuals with high worm burden pre-vaccination. CXCL10 has 424 been shown to promote the recruitment of $CXCR3⁺$ cells, which not only include activated T and B cells ⁴²⁵(62, 63), but also the B-helper Tfh cells important in efficient responses to infection and vaccination (64- 426 66). A CXCL10– inclusive signature was also associated with effective immune responses to a SARS-⁴²⁷CoV-2 vaccine after the 1st vaccination (67), and recent vaccination studies also highlighted a link ⁴²⁸between CXCL10 levels in the serum and innate responses associated with increased vaccine-specific 429 antibody titers (68, 69). Our data, combined with other studies, highlight a vital role for CXCL10 in 430 modulating the early response to vaccination.

431 Notably, it has been demonstrated that deworming can enhance the host immune response to 432 vaccination (25), and some studies have shown that PZQ treatment can partially restore vaccine-induced 433 immune responses (60, 70). While all enrolled individuals in this current study were treated with PZQ at ⁴³⁴D12 post-vaccination (Fig 1), it is possible that *Schistosoma*-related effects on baseline immune responses

⁴³⁵may have already occurred. Furthermore, the rate of reinfection and the extent to which the initial 436 infection was cleared, is also unknown; and as this study also indicates that several proinflammatory 437 cytokines at baseline remain elevated at month 12 post-vaccination, it is possible that individuals with a 438 higher baseline CAA concentration get more reinfections with time, creating a cycle of high CAA 439 concentration driving inefficient immune responses to secondary antigen. Despite these limitations, we 440 observed differences in vaccine-induced responses in individuals with varying pre-vaccinated levels of ⁴⁴¹CAA, irrespective of reported PQZ treatment. A similar observation was seen in an animal study of 442 chronic schistosomiasis and HIV vaccination where schistosomiasis suppressed vaccine responses, and 443 this was maintained regardless of anti-helminth treatment (71). While we know anti-helminth treatment is ⁴⁴⁴effective at clearing worms, results suggest that *Schistosoma* infection in this study is associated with 445 irreversible immunomodulatory effects that can influence a host's response to unrelated antigen, such as 446 those in vaccines.

⁴⁴⁷In this study, we did not evaluate for transgenerational exposure to *Schistosoma*. Previous studies 448 have shown that parasite antigen and maternal antibodies can transfer from mothers to babies in utero and 449 during breastfeeding (72), and some studies have showed lower vaccine responses in the newborns of ⁴⁵⁰*Schistosoma*-infected mothers (73-75). These observations highlight the potential for different baseline ⁴⁵¹immune responses in individuals with transgenerational exposure to *Schistosoma* infection and its effect 452 on vaccine responses needs further investigation. It is also likely that some individuals are genetically 453 more susceptible to *Schistosoma* and related hepatic fibrosis than others (76), and further understanding is 454 needed on how susceptibility and high worm load may contribute to how these individuals mount ⁴⁵⁵effective vaccine responses. In this study we adjusted for age and sex but people with *Schistosoma* may 456 be more likely to have other exposures (including other worm species, different microbiome) (77), which 457 might influence vaccine response.

⁴⁵⁸In summary, high worm burden in *S. mansoni* infection is associated with the dysregulation of 459 vaccine-induced responses by the cooperation of key cytokines/chemokines that lead to elevated 460 inflammation, and lower levels of cytokines that promote the frequency and function of innate and

461 adaptive immune subsets important in generating vaccine-specific antibodies. Furthermore, a high CCL17 ⁴⁶²and low CXCL10-inclusive cytokine/chemokine signature pre-vaccination in instances of high worm ⁴⁶³burden, is also identified. The results from our study could be applied to instruct ongoing and future ⁴⁶⁴projects to benefit vaccination programs in *Schistosoma*- and other helminth- endemic communities, 465 particularly in the design of studies that address specific hypotheses such as recently published study 466 protocols from Nkurunungi and colleagues which describe the effect of a more intensive intervention with ⁴⁶⁷anti-helminth treatment on vaccine responses in adolescents in Uganda (78, 79).

⁴⁶⁹**Methods**

⁴⁷⁰**Study participants and design**

471 Healthy adult volunteers who were enrolled in this study were one-arm of a community-based 472 prospective investigation that took place in fishing communities located in Entebbe, Uganda, called the 473 Stimulated Vaccine Efficacy Trial (SiVET). SiVET was set up to identify populations and assess the 474 implementation of efficacy trial procedures. Hepatitis B and typhoid vaccines were selected as simulated 475 vaccines due to the potential benefit to the fishing communities. Participants aged 18 to 49 years, males 476 and non-pregnant females were enrolled starting in 2015 from one mainland lakeshore fishing community 477 and one island community along Lake Victoria, in Wakiso district. (S1 Table). Inclusion criteria 478 encompassed HIV-uninfected, negative Hep B surface antigen (HbsAg) and core antibody tests, 479 capability, and willingness to provide written informed consent to receive HBV vaccine, and consent for 480 follow-up leading up to 12 months after the first study immunization. Volunteers were not prescreened for 481 active malaria and latent TB infections. Samples from 75 volunteers were available to be used for this 482 present sub-study with the objective to explore predictors of immune responses, (including parasite 483 burden, microbiome, effect of diet on microbiome) and to explore novel methods to identify predictors of 484 vaccine response and pathways activated in effective vaccine immune responses. Adults were screened up 485 to 6 weeks before the first study injection of the Hepatitis B vaccine ENGERIX-B (GlaxoSmithKline 486 Biologicals, derived from recombinant subunit Hepatitis B surface antigen adsorbed on aluminum

487 hydroxide) followed by two booster doses given at months 1 and 6 (Fig 1). Doses were given 488 intramuscularly in the deltoid muscle at 1mL volume containing 20 µg of the vaccine. Whole blood and 489 plasma were collected pre-vaccination (D0), post-1st injection (D3, D7, and D12), and post-booster 490 injections on the day the infections were administered (M1 and M6) (Fig 1). Volunteers were treated at 491 day 12 with Praziquantel (PZQ) as appropriate, for egg counts detected in stool samples at enrollment, ⁴⁹²D3, and/or D7 (Fig 1). *Schistosoma-*infected participants received 40mg/kg body weight single dose 493 (average 2.4 g) of PZQ.

 $\ddot{ }$

⁴⁹⁵**Treatment of** *S. mansoni***-infected enrolled individuals**

496 Stool samples were collected from enrollees' pre-vaccination (D0), prior to the first dose of the 497 HepB vaccine, and at D3 and D7 post-vaccination. *Schistosoma* egg counts were subsequently conducted 498 and if stool sample/s were positive, PZQ treatment was administered at D12 post-vaccination. Egg count 499 results were available within one week, after which any infected individuals were treated.

500

⁵⁰¹**Circulating anodic antigen (CAA) assay**

502 The circulating anodic antigen assay (CAA) was performed pre-vaccination (Day 0) on serum ⁵⁰³samples from enrolled participants to reveal ongoing *Schistosoma* infection (29-32). Human negative 504 serum (Sanquin, blood donors, the Netherlands) was spiked with a known concentration of CAA and 505 dilutions made up to eight standard points to provide an appropriate standard series. An extra negative 506 serum sample was included as a duplicate negative control. Samples were evaluated using the SCAA500 507 protocol with a lower limit of detection threshold of $3pg/mL$; 500 mL serum and standards were extracted 508 with an equal volume of 4% w/v trichloroacetic acid (TCA; Merck Life Science NV, the Netherlands), 509 vortexed and incubated at ambient temperature for five minutes. Thereafter, samples and standards were 510 briefly vortexed and spun at 13000g for five minutes and 0.5 mL of clear supernatant was concentrated to 511 20 mL using Amicon Ultra-0.5 Centrifugal Filter Units devices with a molecular weight cut-off of 10 kDa 512 (Merck Life Science N.V., the Netherlands). Note, for samples with insufficient serum volumes the

513 SCAA20 test format was used which requires only 20uL serum and no concentration step but has a lower 514 limit of detection threshold of $30pg/mL$. The resulting TCA soluble fraction (20μL) was added to wells 515 containing 100 ng dry UCP particles (80) (400 nm $Y_2O_2S:Yb^{3+},Er^{3+}$) coated with mouse monoclonal anti-516 CAA antibodies (32) hydrated with 100 mL of high salt lateral flow buffer (HSFS: 200 mM Tris pH8, 517 270 mM NaCl, 0.5% (v/v) Tween-20, 1% (w/v) BSA. After incubated for one hour at 37° C while shaking 518 at 900rpm the CAA lateral flow strips (32) were placed in the wells, and samples allowed to flow. The 519 strips were then dried overnight and analyzed using an Upcon reader (Labrox Oy, Turku, Finland). The 520 test line signals (T; relative fluorescent units, peak area) were normalized to the flow control signals (FC) 521 of the individual strips and the results expressed as Ratio value ($R=T/FC$).

522

⁵²³**Whole blood processing and sample storage**

524 PBMCs isolation/storage: Whole Blood collected in NaHeparin tube (BD, NJ, USA) was layered 525 over 20ml of Histopaque (Sigma-Aldrich, Darmstadt, Germany) and centrifuged at 400g for 40 minutes at 526 room temperature with no centrifuge brakes. Lymphocytes, platelets, and monocytes found at the plasma-527 separating medium interface (buffy coat) were recovered and washed in Hanks Balanced Salt solution to 528 remove contaminating platelets, separation media and plasma. The resulting PBMCs (lymphocytes and 529 monocytes) were resuspended in complete RPMI media (RPMI 1640 media supplemented with 10% Fetal 530 Bovine Serum (FBS), 10mM Hepes buffer, 2mM L-glutamine, 1mM sodium pyruvate and 1X penicillin-531 streptomycin) for counting and concentrated at 10million cells/mL/ vial in FBS with 10% DMSO, frozen 532 down using a rate-controlled freezer and stored in liquid nitrogen.

⁵³³**Serum separation:** Specific vacutainers for serum (SST, Plymouth UK) were invert twice to mix 534 blood and then centrifuged at 1200 g for 10 minutes at room temperature with maximum acceleration and 535 brake after which aliquots into pre-labeled cryovials were made and stored at below -70 \degree C.

⁵³⁶**Plasma separation:** Plasma from the separation tube of PBMCs was harvested and then 537 centrifuged at 1800 g for 20 minutes at room temperature with maximum acceleration and brake after

538 which aliquots into pre-labeled cryovials without disturbing the platelet pellet at the bottom of the tube 539 and stored at below -70 \degree C.

540

⁵⁴¹**Hepatitis B antibody testing**

542 Each serum sample was assayed at screening using three different HBV infection tests for: 543 Hepatitis B surface antigen (HbsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis B surface 544 antibody (anti-HBs). The HbsAg and antiHBc antibodies were tested for using the VIDAS HbsAg Ultra 545 and VIDAS anti-HBc Total II (Biomerieux SA, France) kits respectively on the MinVidas analyzer. The 546 anti-HBs testing was done using the Cobas e 411 analyzer (Roche Diagnostics, Mannheim, Germany). 547 The anti-HBs titer cut off value was 10IU/L. All three tests were used only at screening to differentiate 548 between possible past exposure from active infection, and to ensure only HepB-negative individuals were 549 recruited and administered the vaccine. Measurement of anti-HBs antibody was conducted for all 550 subsequent follow-up visits.

551

⁵⁵²**PBMC culture**

553 PBMCs from non-infected and *S. mansoni*-infected individuals pre-vaccination and post-554 vaccination were thawed and rested for 3 hours before being placed into culture. Samples were used for ⁵⁵⁵ex-vivo immunostaining and flow cytometry analysis, and for TLR stimulation assays. PBMCs were 556 suspended in RPMI medium supplemented with L-glutamine (Corning Cellgro, Manassas, VA, USA), 557 10% FBS and 1 X [50 U] penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA) (R10F). 1 $x10^6$ cells 558 were added to 5-ml polypropylene tubes for CLO97 stimulation (Imidazoquinoline Compound; TLR7/8 559 agonist) (Invivogen, San Diego, CA, USA), and 0.5×10^6 cells added to the wells of 96-well U-bottom 560 plates for CpG-ODN 2006 stimulation (TLR9 agonist) (Invivogen). Optimal concentration for CLO97 561 stimulation was selected as previously described (81). CpG-ODN 2006 was titrated on CFSE-labeled 562 PBMCs, and optimal TLR9 activity assessed on proliferating CD19⁺ cells by flow cytometry. Cells were 563 allowed to rest at 37°C under a 5% CO^2 atmosphere for 3 hours prior to addition of TLR agonists at the

564 following concentrations: CLO97 (0.5ug/ml) and CpG (1ug/ml). Cells were cultured also at 37° C under a 5% CO² atmosphere for 18hrs (CLO97), and 7 days (CpG-ODN 2006). After culture, PBMCs were 566 collected and washed in preparation for analysis by multiplex immunoassays or flow cytometry. For HBV 567 peptide stimulation, PBMCs were first labeled with CFSE using a Cell Trace™ CFSE cell proliferation 568 kit (ThermoFisher Scientific, Waltham, MA, USA), and rested for 3 hours in the conditions described 569 above. In a 96-well deep well plate (USA Scientific, Ocala, FL, USA), 2 x 10⁶ cells in 1mL RPMI 570 medium supplemented with 8% human serum (Access Biologicals, Vista, CA, USA), 1% penicillin-571 streptomycin and 10ng/mL IL-2 (Miltenyi Biotec, Auburn, CA, USA) (R8H-IL-2) were stimulated with 572 either Pepmix[™] HBV (Large envelope protein) (JPT Peptide Technologies, Berlin, Germany) at 1ug/mL 573 or control (R8H-IL-2 with 0.2% DMSO) on Day 1 and cultured in the conditions described above. On 574 Day 3, cells were supplemented with fresh R8H-IL-2 by half media replacement; and on Day 6, PBMCs 575 were collected and washed in preparation for measurement of immune recall responses by flow 576 cytometry.

577

⁵⁷⁸**Cytokine and chemokine analysis (multiplex immunoassay)**

579 Plasma collected from whole blood and supernatant collected from stimulated PBMCs were 580 analyzed for chemokines/cytokines and Ig isotypes using magnetic bead multiplex assays. The following 581 human analyte premixed panels were used: Bio-Plex human chemokine panel (Bio-Rad, Hercules, CA, 582 USA): I-309 (CCL1), MCP-1 (CCL2), MIP-1α (CCL3), MCP-3 (CCL7), MCP-2 (CCL8), Eotaxin (CCL11), MCP-4 (CCL13), MIP-1α (CCL15), TARC (CCL17), MIP-3β (CCL19), 6Ckine (CCL21), MIP-3α (CCL20), MDC (CCL22), MPIF-1 (CCL23), Eotaxin-2 (CCL24), TECK (CCL25), Eotaxin-3 (CCL26), CTACK (CCL27), GM-CSF, GRO-α (CXCL1), GRO-β (CXCL2), ENA-78 (CXCL5), GCP-2 (CXCL6), MIG (CXCL9), IP-10 (CXCL10), I-TAC (CXCL11), SDF-1A+β (CXCL12), BCA-1 (CXCL13), SCYB16 (CXCL16), Fractalkine (CX3CL1), MIF, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, TNF-α, and IFN-γ. Custom ProcartaPlex 34-plex (ThermoFisher Scientific): APRIL, BAFF, CD30, CD40L, G-CSF, IFN-A, IL-12P70, IL-13, IL-15, IL-16, IL-17A, IL-18, IL-1A, IL-20, IL-21, IL-22, IL-

⁵⁹⁶**Flow cytometry analysis of PBMCs**

597 For ex-vivo analysis, 1×10^6 PBMCs per well were incubated with Fixable aqua viability stain ⁵⁹⁸405 (ThermoFisher Scientific) to discriminate dead from live cells then stained with antibody panels 599 described (S8 and S9 Tables). To detect intracellular expression of markers, cells were fixed and 600 permeabilized using the Foxp3/Transcription factor staining buffer set (ThermoFisher Scientific) and 601 immunostained using FOXP3-FITC (clone, PCH101) (ThermoFisher Scientific) (S8 Table) and KI67-⁶⁰²FITC (BD Biosciences, San Jose, CA, USA) (S9 Table). Following HBV peptide stimulation, PBMCs 603 were stained with the surface antibody panel described (S10 Table), then stained with 7-AAD (BD 604 Biosciences) for 10 minutes prior to analysis to discriminate dead from live cells. Flow cytometry 605 measurements were made on a BD LSRFortessaTM (BD Biosciences) and collected data analyzed using 606 FlowJo software version 10.7.1 (BD).

607

⁶⁰⁸**Antibody-dependent cellular phagocytosis (ADCP) assay**

⁶⁰⁹An antibody-dependent cellular phagocytosis (ADCP) assay to investigate monocyte function ⁶¹⁰was conducted. HbsAg was biotinylated using an EZ-Link™ Sulfo-NHS-LC-Biotinylation Kit ⁶¹¹(ThermoFisher Scientific) and coupled to FluoSpheres™ NeutrAvidin™-Labeled Microspheres 612 (ThermoFisher Scientific). To form immune complexes, antigen-coupled beads were incubated for 2 613 hours at 37° C with 1:25 diluted serum samples and then washed to remove unbound immunoglobulin. 614 After washing, immune complexes were incubated for 16-18 hours with a monocyte cell line, THP-1 cells 615 [25,000 THP-1 cells per well at a concentration of 1.25×105 cells/ml in RPMI (ThermoFisher Scientific)

625 (clone: HP6001; Southern Biotech, AL, USA). For the FcγR binding, a respective PE–streptavidin ⁶²⁶(Agilent Technologies, Santa Clara, CA, USA) coupled recombinant and biotinylated human Fcγ^R 627 protein was used as a secondary probe.

628

⁶²⁹**Statistics**

630 Statistical inference evaluating the differences of HepB titers between non-infected versus low 631 CAA, non-infected versus high CAA and low CAA versus high CAA was determined using Wilcoxon ⁶³²rank-sum test. Wilcoxon rank-sum tests were performed on non-infected vs. low CAA, or non-infected 633 vs. high CAA, or low CAA vs. high CAA within each time point for plasma Luminex assays, and ex-vivo 634 flow cytometry analysis. Pairwise Wilcoxon signed rank test were performed on untreated vs. treated for 635 each non-infected, or low CAA, or high CAA for CpG, HBV-LEP and CLO97 stimulation assays; and 636 within the treated groups, a Wilcoxon rank-sum test was conducted on non-infected vs. low CAA, or non-637 infected vs. high CAA, or low CAA vs. high CAA. Linear regression analyses were adjusted for sex (no 638 significant association between age and HepB titers) and student t-tests were used to evaluate for the 639 significance of the association. Sensitivity analyses were performed using the R package sensemakr (83) 640 used to assess the robustness of the results of the linear regression analysis to an unobserved confounding

641 variable. Benjamini-Hochberg adjustment was used to control for multiple testing for each assay. P \leq 0.05 642 was considered significant for all analyses.

643

⁶⁴⁴**Study approval**

⁶⁴⁵Informed consent was obtained from all participants prior to being enrolled in the studies. All 646 studies were approved by the Uganda Virus Research Institute Research Ethics Committee, reference 647 number GC/127/15/07/439 and the Uganda National Council of Science and Technology, reference 648 number HS 1850.

649

⁶⁵⁰**Author contributions**

⁶⁵¹RM, TM, and SF share first authorship. RM and TM are first and second co-authors respectively, 652 as they conceptualized, designed, and performed experiments, analyzed data, and wrote the manuscript. 653 SF is the third co-author and analyzed data and wrote the manuscript. AK, NK, A Nanvubya, PK, BSB 654 and YM designed the SiVET clinical study. AK, AE, PK, JKL and BSB conceptualized the SiVET study. ⁶⁵⁵YB, JKL, GC, GA, EM, BO, TN, IN, A Namuniina, AS, JM, PKK, VMB, BSB, NK, JN, WS, CJDD, PB 656 and MO performed experiments and analyzed data. PLAMC and GJVD designed clinical assays and 657 PLAMC edited the manuscript. EM, BO, TN, IN, AN, AS, JM, PKK, and NK managed enrollee 658 recruitment and participation in the study. PF, MAP, AME, and RPS provided conceptual advice and 659 edited the manuscript. EKH conceptualized experiments and wrote the manuscript. All authors reviewed 660 and approved the manuscript. RM and EKH had final responsibility for the decision to submit for 661 publication.

⁶⁶³**Acknowledgements**

664 This work was supported by NIH funding as part of Human Immune Project Consortium (HIPC) 665 to EKH and RPS #U19 AI128910. The SiVET was supported by a grant from the United States Agency

666 for International Development (USAID) [USAID reference number AID-OAA-A-16-00032]. The

667 contents are the responsibility of the authors and does not necessarily reflect the views of USAID or the

⁶⁶⁸United States Government. We are grateful to the study participants, and healthcare and research staff

669 from the Immunomodulation and Vaccines Programme and the Pathogen Genomics Phenotype and

670 Immunity Programme at the MRC/UVRI and LSHTM Uganda Research Unit, the UVRI-IAVI HIV

- 671 Vaccine Program at the College of Health Sciences at Makerere University, Kampala-Uganda, and the
- 672 International AIDS Vaccine initiative, for the invaluable contribution to this study.
-

⁶⁷⁴**References**

675

676 1. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021:21(2):83-100. 677 developments. Nat Rev Immunol. 2021;21(2):83-100.
678 2. Zimmermann P, Curtis N. Factors That Influe

678 2. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination.
679 Clin Microbiol Rev. 2019;32(2). 679 Clin Microbiol Rev. 2019;32(2).
680 3. Driciru E, Koopman JPF

680 3. Driciru E, Koopman JPR, Cose S, Siddiqui AA, Yazdanbakhsh M, Elliott AM, et al.
681 Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic

681 Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic
682 Settings. Front Immunol. 2021;12:635985. 682 Settings. Front Immunol. 2021;12:635985.
683 4. Nono JK, Kamdem SD, Musai

683 4. Nono JK, Kamdem SD, Musaigwa F, Nnaji CA, Brombacher F. Influence of schistosomiasis on host vaccine responses. Trends Parasitol. 2022;38(1):67-79. 684 schistosomiasis on host vaccine responses. Trends Parasitol. 2022;38(1):67-79.
685 5. Ssali A. Pickering L. Nalwadda E. Mujumbusi L. Seeley J. I

⁶⁸⁵5. Ssali A, Pickering L, Nalwadda E, Mujumbusi L, Seeley J, Lamberton PHL. 686 Schistosomiasis messaging in endemic communities: Lessons and implications for interventions for interventions for interventions for interventions for interventions for interventions of the Uganda, a rapid ethnographic 687 from rural Uganda, a rapid ethnographic assessment study. PLoS Negl Trop Dis.
688 2021;15(10):e0009893. 688 2021;15(10):e0009893.
689 6. Loewenberg S. U

689 6. Loewenberg S. Uganda's struggle with schistosomiasis. Lancet. 2014;383(9930):1707-8.
690 7. World Health Organization. Assessing the Efficacy of Anthelminthic Drugs agains

690 7. World Health Organization. Assessing the Efficacy of Anthelminthic Drugs against Schistosomiasis and Soil-Transmitted Helminthiases . Geneva, Switzerland: World Health 691 Schistosomiasis and Soil-Transmitted Helminthiases . Geneva, Switzerland: World Health Organization. https://apps.who.int/iris/handle/10665/79019 Accessed on 06/16/2022. 2013. 692 Organization. https://apps.who.int/iris/handle/10665/79019 Accessed on 06/16/2022. 2013.
693 8. Omar HH. Impact of chronic schistosomiasis and HBV/HCV co-infection on the

693 8. Omar HH. Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver:
694 current perspectives. Hepat Med. 2019;11:131-6. 694 current perspectives. Hepat Med. 2019;11:131-6.
695 9. Bwogi J, Braka F, Makumbi I, Mishra V,

695 9. Bwogi J, Braka F, Makumbi I, Mishra V, Bakamutumaho B, Nanyunja M, et al. Hepatitis 696 B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci. 696 B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci.
697 2009;9(2):98-108. 697 2009;9(2):98-108.
698 10. Kafeero HN

698 10. Kafeero HM, Ndagire D, Ocama P, Kudamba A, Walusansa A, Sendagire H. Prevalence
699 and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic

699 and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic
700 review and meta-analysis of epidemiological studies published from 2005 to 2020. Arch Public 700 review and meta-analysis of epidemiological studies published from 2005 to 2020. Arch Public
701 Health. 2021;79(1):167.

Health. 2021;79(1):167.

702 11. Kitandwe PK, Muyanja E, Nakaweesa T, Nanvubya A, Ssetaala A, Mpendo J, et al.
703 Hepatitis B prevalence and incidence in the fishing communities of Lake Victoria, Uganda: a 703 Hepatitis B prevalence and incidence in the fishing communities of Lake Victoria, Uganda: a
704 retrospective cohort study. BMC Public Health. 2021;21(1):394.

- 704 retrospective cohort study. BMC Public Health. 2021;21(1):394.
705 12. Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Her 705 12. Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B Vaccines. J Infect Dis.
706 2021:224(12 Suppl 2):S343-S51. 706 2021;224(12 Suppl 2):S343-S51.
707 13. Walayat S, Ahmed Z, M
- 707 13. Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol.
- 708 vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol.
709 2015:7(24):2503-9. 709 2015;7(24):2503-9.
710 14. Kamdem SI
- 710 14. Kamdem SD, Moyou-Somo R, Brombacher F, Nono JK. Host Regulators of Liver
711 Fibrosis During Human Schistosomiasis. Front Immunol. 2018;9:2781. 711 Fibrosis During Human Schistosomiasis. Front Immunol. 2018;9:2781.
712 15. Angeles JMM, Mercado VJP, Rivera PT. Behind Enemy Li
- 712 15. Angeles JMM, Mercado VJP, Rivera PT. Behind Enemy Lines: Immunomodulatory
713 Armamentarium of the Schistosome Parasite. Front Immunol. 2020;11:1018. 713 Armamentarium of the Schistosome Parasite. Front Immunol. 2020;11:1018.
714 16. Zheng B, Zhang J, Chen H, Nie H, Miller H, Gong Q, et al. T Ly.
- 714 16. Zheng B, Zhang J, Chen H, Nie H, Miller H, Gong Q, et al. T Lymphocyte-Mediated
715 Liver Immunopathology of Schistosomiasis. Front Immunol. 2020;11:61. 715 Liver Immunopathology of Schistosomiasis. Front Immunol. 2020;11:61.
716 17. Lundy SK, Lukacs NW. Chronic schistosome infection leads to m
- 716 17. Lundy SK, Lukacs NW. Chronic schistosome infection leads to modulation of granuloma
717 formation and systemic immune suppression. Front Immunol. 2013;4:39. 717 formation and systemic immune suppression. Front Immunol. 2013;4:39.
718 18. Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular He
- 718 18. Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular Helper T Cells. Annu Rev
719 Immunol. 2016;34:335-68. 719 Immunol. 2016;34:335-68.
720 19. Crotty S. T Follici
- 720 19. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases.
721 Immunity. 2019;50(5):1132-48. 721 Immunity. 2019;50(5):1132-48.
722 20. Su Z, Segura M, Steven
- 722 20. Su Z, Segura M, Stevenson MM. Reduced protective efficacy of a blood-stage malaria
723 vaccine by concurrent nematode infection. Infect Immun. 2006;74(4):2138-44. vaccine by concurrent nematode infection. Infect Immun. 2006;74(4):2138-44.
724 21. Elias D. Akuffo H. Pawlowski A. Haile M. Schon T. Britton S. Sch
- 724 21. Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S. Schistosoma mansoni
725 infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium 725 infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium
726 tuberculosis. Vaccine. 2005;23(11):1326-34. 726 tuberculosis. Vaccine. 2005;23(11):1326-34.
727 22. Chen L, Liu WQ, Lei JH, Guan I
- 727 22. Chen L, Liu WQ, Lei JH, Guan F, Li MJ, Song WJ, et al. Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One. 728 japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One.
729 2012;7(12):e51512. 729 2012;7(12):e51512.
730 23. Nono JK, K
- 730 23. Nono JK, Kamdem SD, Netongo PM, Dabee S, Schomaker M, Oumarou A, et al.
731 Schistosomiasis Burden and Its Association With Lower Measles Vaccine Responses in School 731 Schistosomiasis Burden and Its Association With Lower Measles Vaccine Responses in School
732 Children From Rural Cameroon. Front Immunol. 2018:9:2295.
- 732 Children From Rural Cameroon. Front Immunol. 2018;9:2295.
733 24. Tweyongyere R, Nassanga BR, Muhwezi A, Odongo 733 24. Tweyongyere R, Nassanga BR, Muhwezi A, Odongo M, Lule SA, Nsubuga RN, et al.
734 Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles 734 Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles
735 catch-up immunisation in pre-school children: A randomised trial. PLoS Negl Trop Dis. 735 catch-up immunisation in pre-school children: A randomised trial. PLoS Negl Trop Dis.
736 2019;13(2):e0007157. 736 2019;13(2):e0007157.
737 25. Song WJ, Che
- 737 25. Song WJ, Cheng YL, Liu LZ, Kong Z, Hu S, Liu K, et al. [Impact of chronic schistosomiasis japonica on the protective immunity induced by vaccine against hepatitis B 738 schistosomiasis japonica on the protective immunity induced by vaccine against hepatitis B
739 virus]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2005;23(3):163-5.
- 739 virus]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2005;23(3):163-5.
740 26. Riner DK, Ndombi EM, Carter JM, Omondi A, Kittur N, Kavere E, et al. Schisto 740 26. Riner DK, Ndombi EM, Carter JM, Omondi A, Kittur N, Kavere E, et al. Schistosoma
741 mansoni Infection Can Jeopardize the Duration of Protective Levels of Antibody Responses to 741 mansoni Infection Can Jeopardize the Duration of Protective Levels of Antibody Responses to
742 Immunizations against Hepatitis B and Tetanus Toxoid. PLoS Negl Trop Dis. 742 Immunizations against Hepatitis B and Tetanus Toxoid. PLoS Negl Trop Dis.
743 2016:10(12):e0005180.
- ⁷⁴³2016;10(12):e0005180. 744 27. Alan Wilson R, van Dam GJ, Kariuki TM, Farah IO, Deelder AM, Coulson PS. The detection limits for estimates of infection intensity in schistosomiasis mansoni established by a
- 745 detection limits for estimates of infection intensity in schistosomiasis mansoni established by a
746 study in non-human primates. Int J Parasitol. 2006;36(12):1241-4.
- study in non-human primates. Int J Parasitol. $2006;36(12):1241-4$.

747 28. van Dam GJ, Bogitsh BJ, van Zeyl RJ, Rotmans JP, Deelder AM. Schistosoma mansoni:
748 in vitro and in vivo excretion of CAA and CCA by developing schistosomula and adult worms. J

748 in vitro and in vivo excretion of CAA and CCA by developing schistosomula and adult worms. J
749 Parasitol. 1996;82(4):557-64. 749 Parasitol. 1996;82(4):557-64.
750 29. Corstjens P, de Dood

750 29. Corstjens P, de Dood CJ, Knopp S, Clements MN, Ortu G, Umulisa I, et al. Circulating 751 Anodic Antigen (CAA): A Highly Sensitive Diagnostic Biomarker to Detect Active Schistosoma 751 Anodic Antigen (CAA): A Highly Sensitive Diagnostic Biomarker to Detect Active Schistosoma
752 Infections-Improvement and Use during SCORE. Am J Trop Med Hyg. 2020;103(1 Suppl):50-Infections-Improvement and Use during SCORE. Am J Trop Med Hyg. 2020;103(1_Suppl):50-7. 753 7.
754 30.

754 30. Corstjens P, Hoekstra PT, de Dood CJ, van Dam GJ. Utilizing the ultrasensitive
755 Schistosoma up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA) 755 Schistosoma up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA)
756 assay for sample pooling-strategies. Infect Dis Poverty. 2017;6(1):155. 756 assay for sample pooling-strategies. Infect Dis Poverty. 2017;6(1):155.
757 31. Corstiens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Ka

757 31. Corstjens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Kariuki TM, et al. Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays 758 diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays
759 and upconverting phosphor labels. Parasitology. 2014;141(14):1841-55. 759 and upconverting phosphor labels. Parasitology. 2014;141(14):1841-55.
760 32. Corstjens PL, van Lieshout L, Zuiderwijk M, Kornelis D, Tanke

760 32. Corstjens PL, van Lieshout L, Zuiderwijk M, Kornelis D, Tanke HJ, Deelder AM, et al.
761 Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma 761 Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma circulating anodic antigen in serum. J Clin Microbiol. 2008;46(1):171-6. 762 circulating anodic antigen in serum. J Clin Microbiol. 2008;46(1):171-6.
763 33. Corstjens PL, Nyakundi RK, de Dood CJ, Kariuki TM, Ochola

763 33. Corstjens PL, Nyakundi RK, de Dood CJ, Kariuki TM, Ochola EA, Karanja DM, et al.
764 Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma 764 Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma
765 infections by using larger sample volumes. Parasit Vectors. 2015;8:241. 765 infections by using larger sample volumes. Parasit Vectors. 2015;8:241.
766 34. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, W

766 34. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, et al. Selective
767 recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines 767 recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines
768 thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 768 thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol.
769 1999:11(1):81-8.

769 1999;11(1):81-8.
770 35. Lieberam 770 35. Lieberam I, Forster I. The murine beta-chemokine TARC is expressed by subsets of dendritic cells and attracts primed CD4+ T cells. Eur J Immunol. 1999;29(9):2684-94. 771 dendritic cells and attracts primed CD4+ T cells. Eur J Immunol. 1999;29(9):2684-94.
772 36. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al. C

772 36. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al. CCL17 and
773 CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ 773 CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. $2008;122(10):2286-93$. 774 regulatory T cells in gastric cancer. Int J Cancer. 2008;122(10):2286-93.
775 37. Sharma A, Rudra D. Emerging Functions of Regulatory T Cells

775 37. Sharma A, Rudra D. Emerging Functions of Regulatory T Cells in Tissue Homeostasis.
776 Front Immunol. 2018;9:883. 776 Front Immunol. 2018;9:883.
777 38. Damoiseaux J. The I

777 38. Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin Immunol. 2020;218:108515. 778 soluble IL-2 receptor. Clin Immunol. 2020;218:108515.
779 39. Morita R, Schmitt N, Bentebibel SE, Ranganat

779 39. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al.
780 Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain 780 Human blood $\text{CXCR5}(+) \text{CD4}(+)$ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108-21. 781 specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108-21.
782 40. Cubas R, van Grevenynghe J, Wills S, Kardava L, Santich BH, Buckner CM, e

782 40. Cubas R, van Grevenynghe J, Wills S, Kardava L, Santich BH, Buckner CM, et al.
783 Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during 783 Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during
784 Chronic HIV Infection. J Immunol. 2015;195(12):5625-36.

784 Chronic HIV Infection. J Immunol. 2015;195(12):5625-36.
785 41. Muir R, Metcalf T, Tardif V, Takata H, Phanuphak

785 41. Muir R, Metcalf T, Tardif V, Takata H, Phanuphak N, Kroon E, et al. Altered Memory
786 Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection. PLoS Pathog. 786 Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection. PLoS Pathog.
787 2016;12(7):e1005777. 787 2016;12(7):e1005777.
788 42. Yin M, Xiong '

788 42. Yin M, Xiong Y, Liang D, Tang H, Hong Q, Liu G, et al. Circulating Tfh cell and subsets
789 distribution are associated with low-responsiveness to hepatitis B vaccination. Mol Med. 789 distribution are associated with low-responsiveness to hepatitis B vaccination. Mol Med.
790 2021:27(1):32. ⁷⁹⁰2021;27(1):32.

791 43. Ellebedy AH, Jackson KJ, Kissick HT, Nakaya HI, Davis CW, Roskin KM, et al.
792 Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral

- 792 Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral
793 infection or vaccination. Nat Immunol. 2016;17(10):1226-34. 793 infection or vaccination. Nat Immunol. 2016;17(10):1226-34.
794 44. Colley DG, Secor WE. Immunology of human sc
- 794 44. Colley DG, Secor WE. Immunology of human schistosomiasis. Parasite Immunol.
795 2014;36(8):347-57. 795 2014;36(8):347-57.
796 45. Boyaka PN.
- 796 45. Boyaka PN. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery
797 Systems. J Immunol. 2017;199(1):9-16. 797 Systems. J Immunol. 2017;199(1):9-16.
798 46. Hopkins PA, Sriskandan S. Ma
- 798 46. Hopkins PA, Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond.
799 Clin Exp Immunol. 2005:140(3):395-407. 799 Clin Exp Immunol. 2005;140(3):395-407.
800 47. Krathwohl MD, Anderson JL. Ch
- 800 47. Krathwohl MD, Anderson JL. Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model. Vaccine. 2006:24(15):2987-93. 801 immune response to injected antigens in a mouse model. Vaccine. 2006;24(15):2987-93.
802 48. Majumder S, Bhattacharjee S, Paul Chowdhury B, Majumdar S. CXCL10 is cri
- 802 48. Majumder S, Bhattacharjee S, Paul Chowdhury B, Majumdar S. CXCL10 is critical for the generation of protective CD8 T cell response induced by antigen pulsed CpG-ODN activated 803 the generation of protective CD8 T cell response induced by antigen pulsed CpG-ODN activated dendritic cells. PLoS One. 2012;7(11):e48727.
- 804 dendritic cells. PLoS One. 2012;7(11):e48727.
805 49. Yan Y, Chen R, Wang X, Hu K, Huar 805 49. Yan Y, Chen R, Wang X, Hu K, Huang L, Lu M, et al. CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. Front Cell Dev 806 Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. Front Cell Dev
807 Biol. 2019;7:212.
- 807 Biol. 2019;7:212.
808 50. Stubbs VE 808 50. Stubbs VE, Power C, Patel KD. Regulation of eotaxin-3/CCL26 expression in human monocytic cells. Immunology. 2010;130(1):74-82.
- 809 monocytic cells. Immunology. 2010;130(1):74-82.
810 51. Kraynyak KA, Kutzler MA, Cisper NJ, Kl 810 51. Kraynyak KA, Kutzler MA, Cisper NJ, Khan AS, Draghia-Akli R, Sardesal NY, et al.
811 Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in
- 811 Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine. 2010;28(8):1942-51.
- 812 mice and macaques. Vaccine. 2010;28(8):1942-51.
813 52. Dinarello CA. Overview of the IL-1 fa 813 52. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8-27. 814 immunity. Immunol Rev. 2018;281(1):8-27.
815 53. Saraiva M, O'Garra A. The regulati
- 815 53. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170-81. 816 Immunol. 2010;10(3):170-81.
817 54. Barenbold O, Raso G,
- 817 54. Barenbold O, Raso G, Coulibaly JT, N'Goran EK, Utzinger J, Vounatsou P. Estimating
818 sensitivity of the Kato-Katz technique for the diagnosis of Schistosoma mansoni and hookworm 818 sensitivity of the Kato-Katz technique for the diagnosis of Schistosoma mansoni and hookworm
819 in relation to infection intensity. PLoS Negl Trop Dis. 2017;11(10):e0005953.
- 819 in relation to infection intensity. PLoS Negl Trop Dis. 2017;11(10):e0005953.
820 55. Basch PF. Schistosomes: development, reproduction, and host relation 820 55. Basch PF. Schistosomes : development, reproduction, and host relations. United States:
821 New York : Oxford University Press: 1991. 821 New York : Oxford University Press; 1991.
822 56. Wirnsberger G, Hebenstreit D, Po.
- 822 56. Wirnsberger G, Hebenstreit D, Posselt G, Horejs-Hoeck J, Duschl A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol. 2006;36(7):1882-91.
- 823 expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol. 2006;36(7):1882-91.
824 57. Olatunde AC, Hale JS, Lamb TJ. Cytokine-skewed Tfh cells: functional consequences for 824 57. Olatunde AC, Hale JS, Lamb TJ. Cytokine-skewed Tfh cells: functional consequences for B cell help. Trends Immunol. 2021;42(6):536-50. 825 B cell help. Trends Immunol. 2021;42(6):536-50.
826 58. Oin L. Waseem TC. Sahoo A. Bieerkehaz
- 826 58. Qin L, Waseem TC, Sahoo A, Bieerkehazhi S, Zhou H, Galkina EV, et al. Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology. Front
- 827 the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology. Front 828 Immunol. 2018;9:1884. 828 Immunol. 2018;9:1884.
829 59. Romano A, Hou
- 829 59. Romano A, Hou X, Sertorio M, Dessein H, Cabantous S, Oliveira P, et al. FOXP3+
830 Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma iaponicum:
- 830 Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma japonicum:
831 The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly. PLoS Negl Trop 831 The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly. PLoS Negl Trop
832 Dis. 2016;10(1):e0004306.
-
- 832 Dis. 2016;10(1):e0004306.
833 60. Musaigwa F, Kame 833 60. Musaigwa F, Kamdem SD, Mpotje T, Mosala P, Abdel Aziz N, Herbert DR, et al.
834 Schistosoma mansoni infection induces plasmablast and plasma cell death in the bone marrow
- 834 Schistosoma mansoni infection induces plasmablast and plasma cell death in the bone marrow
835 and accelerates the decline of host vaccine responses. PLoS Pathog. 2022;18(2):e1010327.
- and accelerates the decline of host vaccine responses. PLoS Pathog. 2022;18(2):e1010327.

836 61. Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and 837 mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and
838 are associated with protection against subsequent infection. Mucosal Immunol. 2022. 838 are associated with protection against subsequent infection. Mucosal Immunol. 2022.
839 62. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors:

839 62. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659-702. 840 cells for host defense and immunity. Annu Rev Immunol. 2014;32:659-702.
841 63. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al

841 63. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor 842 infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011;22(3):121-30. 843 Rev. 2011;22(3):121-30.
844 64. Locci M. Havena

- 844 64. Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, et al.
845 Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and 845 Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013;39(4):758-69. 846 correlate with broadly neutralizing HIV antibody responses. Immunity. 2013;39(4):758-69.
847 65. Bentebibel SE, Khurana S, Schmitt N, Kurup P, Mueller C, Obermoser G,
- 847 65. Bentebibel SE, Khurana S, Schmitt N, Kurup P, Mueller C, Obermoser G, et al.
848 ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity 848 ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity
849 antibodies following influenza vaccination. Sci Rep. 2016;6:26494. 849 antibodies following influenza vaccination. Sci Rep. 2016;6:26494.
850 66. Zhang J, Liu W, Wen B, Xie T, Tang P, Hu Y, et al. Circ
- 850 66. Zhang J, Liu W, Wen B, Xie T, Tang P, Hu Y, et al. Circulating CXCR3(+) Tfh cells
851 positively correlate with neutralizing antibody responses in HCV-infected patients. Sci Rep. 851 positively correlate with neutralizing antibody responses in HCV-infected patients. Sci Rep.
852 2019;9(1):10090.
- 852 2019;9(1):10090.
853 67. Bergamasc 853 67. Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D, et al. Systemic IL-15, IFN-gamma, and IP-10/CXCL10 signature associated with effective immune response to SARS-854 IFN-gamma, and IP-10/CXCL10 signature associated with effective immune response to SARS-
855 CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6):109504.
- 855 CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6):109504.
856 68. Goncalves E, Bonduelle O, Soria A, Loulergue P, Rousseau A, Cac
- 856 68. Goncalves E, Bonduelle O, Soria A, Loulergue P, Rousseau A, Cachanado M, et al.
857 Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination. 857 Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination.
858 J Clin Invest. 2019;129(5):1960-71. 858 J Clin Invest. 2019;129(5):1960-71.
859 69. Rechtien A, Richert L, Lore
- 859 69. Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, et al. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses 860 Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses
861 to the Ebola Vaccine rVSV-ZEBOV. Cell Rep. 2017;20(9):2251-61. 861 to the Ebola Vaccine rVSV-ZEBOV. Cell Rep. 2017;20(9):2251-61.
862 70. Nono JK, Mpotje T, Mosala P, Aziz NA, Musaigwa F, F.
- 862 70. Nono JK, Mpotje T, Mosala P, Aziz NA, Musaigwa F, Hlaka L, et al. Praziquantel
863 Treatment of Schistosoma mansoni Infected Mice Renders Them Less Susceptible to 863 Treatment of Schistosoma mansoni Infected Mice Renders Them Less Susceptible to Reinfection. Front Immunol. 2021:12:748387.
- 864 Reinfection. Front Immunol. 2021;12:748387.
865 71. Dzhivhuho GA, Rehrl SA, Ndlovu H, I 865 71. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 866 al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140
867 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated 867 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. PLoS Pathog. 2018;14(7):e1007182. 868 pathology in a mouse model. PLoS Pathog. 2018;14(7):e1007182.
869 72. Attallah AM, Ghanem GE, Ismail H, El Waseef AM. I
- 869 72. Attallah AM, Ghanem GE, Ismail H, El Waseef AM. Placental and oral delivery of Schistosoma mansoni antigen from infected mothers to their newborns and children. Am J Trop 870 Schistosoma mansoni antigen from infected mothers to their newborns and children. Am J Trop 871 Med Hyg. 2003;68(6):647-51.
- 871 Med Hyg. 2003;68(6):647-51.
872 73. Ghaffar YA, Kamel M. 872 73. Ghaffar YA, Kamel M, el-Sobky M, Bahnasy R, Strickland GT. Response to hepatitis B vaccine in infants born to mothers with schistosomiasis. Lancet. 1989;2(8657):272. 873 vaccine in infants born to mothers with schistosomiasis. Lancet. 1989;2(8657):272.
874 74. Malhotra I, LaBeaud AD, Morris N, McKibben M, Mungai P, Muchiri I
- 874 74. Malhotra I, LaBeaud AD, Morris N, McKibben M, Mungai P, Muchiri E, et al. Cord
875 Blood Antiparasite Interleukin 10 as a Risk Marker for Compromised Vaccine Immunogenicity 875 Blood Antiparasite Interleukin 10 as a Risk Marker for Compromised Vaccine Immunogenicity
876 in Early Childhood. J Infect Dis. 2018;217(9):1426-34. 876 in Early Childhood. J Infect Dis. 2018;217(9):1426-34.
877 75. Ondigo BN, Muok EMO, Oguso JK, Njenga Sl
- 877 75. Ondigo BN, Muok EMO, Oguso JK, Njenga SM, Kanyi HM, Ndombi EM, et al. Impact of Mothers' Schistosomiasis Status During Gestation on Children's IgG Antibody Responses to
- 878 of Mothers' Schistosomiasis Status During Gestation on Children's IgG Antibody Responses to
879 Routine Vaccines 2 Years Later and Anti-Schistosome and Anti-Malarial Responses by
- 879 Routine Vaccines 2 Years Later and Anti-Schistosome and Anti-Malarial Responses by Neonates in Western Kenya. Front Immunol. 2018;9:1402.
	- Neonates in Western Kenya. Front Immunol. 2018;9:1402.

881 76. Mewamba EM, Nyangiri OA, Noyes HA, Egesa M, Matovu E, Simo G. The Genetics of Human Schistosomiasis Infection Intensity and Liver Disease: A Review. Front Immunol. 882 Human Schistosomiasis Infection Intensity and Liver Disease: A Review. Front Immunol.
883 2021;12:613468. 883 2021;12:613468.
884 77. Lund AJ,

884 77. Lund AJ, Sokolow SH, Jones IJ, Wood CL, Ali S, Chamberlin A, et al. Exposure, hazard, 885 and vulnerability all contribute to Schistosoma haematobium re-infection in northern Senegal. 885 and vulnerability all contribute to Schistosoma haematobium re-infection in northern Senegal.
886 PLoS Negl Trop Dis. 2021;15(10):e0009806.

886 PLoS Negl Trop Dis. 2021;15(10):e0009806.
887 78. Nkurunungi G, Zirimenya L, Nassuun 887 78. Nkurunungi G, Zirimenya L, Nassuuna J, Natukunda A, Kabuubi PN, Niwagaba E, et al.
888 Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural 888 Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural
889 Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation 889 Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation differences in VACcine responses' (POPVAC) programme. BMJ Open. 2021;11(2):e040426. 890 differences in VACcine responses' (POPVAC) programme. BMJ Open. 2021;11(2):e040426.
891 79. Nkurunungi G. Zirimenya L. Natukunda A. Nassuuna J. Oduru G. Ninsiima C. et

891 79. Nkurunungi G, Zirimenya L, Natukunda A, Nassuuna J, Oduru G, Ninsiima C, et al.
892 Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting 892 Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting
893 analyses for three linked, randomised controlled trials assessing the role, reversibility and 893 analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics. BMJ Open. 894 mediators of immunomodulation by chronic infections in the tropics. BMJ Open.
895 2021;11(2):e040425.

895 2021;11(2):e040425.
896 80. Corstiens PL. 896 80. Corstjens PL, Li S, Zuiderwijk M, Kardos K, Abrams WR, Niedbala RS, et al. Infrared up-converting phosphors for bioassays. IEE Proc Nanobiotechnol. 2005;152(2):64-72. 897 up-converting phosphors for bioassays. IEE Proc Nanobiotechnol. 2005;152(2):64-72.
898 81. Metcalf TU, Cubas RA, Ghneim K, Cartwright MJ, Grevenynghe JV, Richner

898 81. Metcalf TU, Cubas RA, Ghneim K, Cartwright MJ, Grevenynghe JV, Richner JM, et al.
899 Global analyses revealed age-related alterations in innate immune responses after stimulation of 899 Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell. 2015;14(3):421-32.

900 pathogen recognition receptors. Aging Cell. 2015;14(3):421-32.
901 82. Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Ke 901 82. Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Kellogg C, Alter G, et al. High-
902 throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J 902 throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J
903 Immunol Methods. 2012;386(1-2):117-23. 903 Immunol Methods. 2012;386(1-2):117-23.
904 83. Cinelli CaHC. Making sense of sens

904 83. Cinelli CaHC. Making sense of sensitivity: extending omitted
905 variable bias. Journal of the Royal Statistical Society Series B

905 variable bias. Journal of the Royal Statistical Society Series B (Statistical Methodology).
906 2020:82(1):39-67. ⁹⁰⁶2020;82(1):39-67.

907

⁹⁰⁸**Figure captions**

⁹⁰⁹**Fig 1. Clinical study design.** Participants enrolled in the clinical study (n =79, four donor samples were

910 unavailable for analysis in this study) were vaccinated at baseline $[(pre-vacciination) day 0 (D0)]$ and

911 received two boosters at month 1 (M1) and month 6 (M6). Individuals provided sera samples at D0,

912 month 7 post-vaccination (M7) (one month post-booster 2) and month 12 post-vaccination (M12) (six

913 months post-booster 2), which were used to screen for Hepatitis B (HepB) antibody titers. Enrollees were

914 treated at day 12 post-vaccination (D12) with Praziquantel (PZQ) as appropriate, for egg counts detected

915 in stool samples which were collected at D0 (and day 3 and/or day 7). Sera samples at D0 were also used

916 to evaluate for schistosome-specific antigen (circulating anodic antigen, CAA). PMBCs and plasma were

917 also collected at D0, D12, M7 and M12 for subsequent analysis. X denotes corresponding samples 918 collected at that timepoint.

919

⁹²⁰**Fig 2. Higher CAA concentration pre-vaccination is associated with a reduction in Hepatitis B** ⁹²¹**vaccine titers.** (A) Density of Schistosome-specific antigen values (CAA [pg/ml]) analyzed in serum 922 samples from participants pre-vaccination (D0). A binomial distribution was fitted to the CAA values and 923 a maximum-likelihood was used to identify the optimum cutoff separating the two modes of the CAA 924 values. Two groups of participants were then identified based on CAA values, low CAA \langle <36pg/mL 925 CAA), n =41; and high CAA (\geq 36pg/mL CAA), n =33. Male (blue line), n =53; Female (red line), n =21 926 (B) Hepatitis B (HepB) titers (log pg/mL) determined by commercial immunoassays for individuals at 927 M7 post-vaccination plotted to compare low and high CAA. Participants were further defined based on 928 CAA concentration values using methodology from the CAA assay that allowed detection of samples as 929 low as 3pg/mL: non-infected [no] (<3pg/mL CAA), low CAA [low] (3-100 pg/mL CAA), and high CAA 930 [high] $(>100pg/mL$ CAA) (C) HepB titers for individuals at Month 7 post-vaccination, non-infected, n 931 = 16, low CAA, n = 26 and high CAA, n = 22 and (D) Month 12 post-vaccination, non-infected, n = 14, low 932 CAA, $n = 23$, and high CAA, $n = 19$ plotted to compare CAA. Boxplots show median values (horizontal 933 line), interquartile range (box) and 95% confidence interval (whiskers).

⁹³⁵**Fig 3. Elevated levels of plasma cytokines/chemokines involved in lymphocyte cell migration and** 936 **activation pre-vaccination in individuals with** *S. mansoni* **infection persist at month 12 post-**⁹³⁷**vaccination.** (A) CCL17, (B) CCL19, and (C) CXCL9 levels in the plasma of non-infected individuals 938 pre-vaccination (D0), n =19, low CAA, n =32, and high CAA, n =24, and M12 post-vaccination, n =15, 939 low CAA, n =29, and high CAA, n =19. Data shown as \pm SEM. * P \leq 0.05. Wilcoxon rank-sum test 940 performed on non-infected vs. low CAA, or non-infected vs. high CAA, or low CAA vs. high CAA 941 within each time point D0 or M12. Non-infected- light grey, low CAA - blue, and high CAA - dark grey. ⁹⁴²(D) Principal component analysis of plasma cytokines/chemokines pre-vaccination and after Hepatitis B

943 vaccination was conducted and the first (PC1) and second (PC2) principal components were used to plot 944 samples based on their plasma cytokines/chemokines profiles. Each dot corresponds to a sample and 945 colors denote the timepoint the sample was collected: D0- red, D3- green, D7- blue, and M12- purple.

⁹⁴⁷**Fig 4. Frequencies of circulating follicular helper (cTfh) cells are lower pre- and post-vaccination in** ⁹⁴⁸*S. mansoni* **infection with concurrent higher frequencies of regulatory T cells (Tregs) in individuals** 949 with high CAA concentration. Frequencies of CD3⁺CD45RA⁻CD45RA⁻CD25⁻CXCR5⁺, populations: (A) 950 cTfh1 [CXCR3⁺], (B) cTfh2 [CXCR3⁻CCR6⁻], (C) cTfh17 [CXCR3⁻CCR6⁺], (D) non cTfh 951 [CD3⁺CD4⁺CD45RA⁻CD25⁻CXCR5⁻] and (E) CXCR5⁻Tregs [CD3⁺CD4⁺CD45RA⁻CD127⁻ and (E) CXCR5^Tregs Tregs [CD3⁺CD4⁺CD45RA⁻ 952 CD25⁺Foxp3⁺CXCR5⁻ were identified by flow cytometry of PBMCs from individuals pre-vaccination 953 (D0) non-infected, n =19, low CAA, n =31, and high CAA, n =25, M7 post-vaccination non-infected, n 954 = 14, low CAA, n =17, and high CAA, n = 20, and M12 post-vaccination non-infected, n =16, low CAA, n 955 = 24, and high CAA, n = 20. Data shown as \pm SEM. *P \leq 0.05. Wilcoxon rank-sum test performed on non-956 infected vs. low CAA, or non-infected vs. high CAA, or low CAA vs. high CAA for each time point 957 separately D0, M7, or M12. Non-infected- light grey, low CAA - blue, and high CAA - dark grey.

958

⁹⁵⁹**Fig 5. Frequencies of antibody secreting cells (ASCs) are lower at month 12 post-vaccination in** 960 **individuals with high CAA concentration.** Frequencies of (A) KI67⁺ ASCs [CD19⁺CD10^TgD⁻ 961 CD71⁺CD38⁺CD20⁻], (B) IgG⁺ ASCs, and (C) IgA⁺ ASCs, were identified by flow cytometry of PBMCs 962 from individuals pre-vaccination (D0) non-infected, n =16, low CAA, n =29, and high CAA, n =24, M7 963 post-vaccination non-infected, $n = 14$, low CAA, $n = 17$, and high CAA, $n = 20$, and M12 post-vaccination 964 non-infected, n =16, low CAA, n =23, and high CAA, n =21. Data shown as \pm SEM. * P \leq 0.05. 965 Wilcoxon rank-sum test performed on non-infected vs. low CAA, or non-infected vs. high CAA, or low 966 CAA vs. high CAA for each time point separately D0, M7, or M12. Non-infected- light grey, low CAA -967 blue, and high CAA - dark grey.

968

⁹⁶⁹**Fig 6. Changes in the Ig isotype profile are evident in** *S. mansoni* **infection pre- and post-vaccination** 970 **in response to TLR9 stimulation.** (A) IgG4 levels pre-vaccination (D0), and (C) IgA levels at M12 post-971 vaccination in the culture supernatant of PBMCs stimulated for 7 days with CpG (CpG-ODN [TLR9]) or 972 UNT (untreated). D0 non-infected, $n = 14$, low CAA, $n = 27$, and high CAA, $n = 21$, and M12 post-973 vaccination non-infected, n =10, low CAA, n =20, and high CAA, n =17. Data shown as \pm SEM. * P \leq 974 0.05. Wilcoxon matched-pairs signed rank test performed on UNT vs. CpG for each non-infected, or low 975 CAA, or high CAA, and within the CpG-treated group a Wilcoxon rank-sum test on non-infected vs. low 976 CAA, or non-infected vs. high CAA, or low CAA vs. high CAA. Non-infected- light grey, low CAA -977 blue, and high CAA - dark grey. (B) The mean Florescence intensity (MFI) of serum *S. mansoni*-specific 978 IgG4 at D0 non-infected [no], n =15, low CAA [low], n =21, and high CAA [high], n =20). A student t-979 test was used to evaluate for the significance of the correlation. $P < 0.05$ was considered significant.

Fig 7. Hepatitis B peptide-specific memory CD4⁺ T cells positively correlate with Hepatitis B titers ⁹⁸²**at month 7 post-vaccination, with a concurrent negative correlation for Hepatitis B peptide-specific memory CD8⁺ T cells.** Frequencies of CFSE⁻ (A) CD4⁺CD45RA⁻ memory T (CD4⁺ mem), and (B) 984 CD8⁺CD45RA⁻ memory T cells (CD8⁺ mem), were identified by flow cytometry of PBMCs from 985 individuals at M7 post vaccination non-infected, n =12, low CAA, n =10, and high CAA, n =15, that were 986 stimulated for 6 days with hepatitis B long envelope protein peptide (HBV LEP) or DMSO control 987 (control). Data shown as \pm SEM. * P \leq 0.05. Wilcoxon matched-pairs signed rank test performed on 988 control vs. HBV LEP for each non-infected, or low CAA, or high CAA, and within the HBV-LEP-treated 989 group a Wilcoxon rank-sum test on non-infected vs. low CAA, or non-infected vs. high CAA, or low 990 CAA vs. high CAA within the CpG-treated. Non-infected- light grey, low CAA - blue, and high CAA -991 dark grey. (C) Linear regressions were fit between Hepatitis B titers and CFSE (C) CD4⁺ mem, and (D) 992 CD8⁺ mem T cell populations adjusted for sex and student t-tests were used to evaluate for the 993 significance of the association. t (t-statistic). $P \le 0.05$ was considered significant. (Shape: triangle-Male, 994 circle-Female; color: grey- non-infected, black- low CAA, blue- high CAA).

⁹⁹⁶**Fig 8. Monocyte function is important in and significantly correlate with Hepatitis B vaccine** 997 **responses**. Antibody-dependent cellular phagocytosis (ADCP) assays with serum from individuals pre-998 vaccination, non-infected, n =14, low CAA, n =20, and high CAA, n =18, were conducted with cells from 999 the monocyte cell line THP-1. Scatter plots show HBsAg-specific ADCP associations with (A) Hepatitis ¹⁰⁰⁰B titers at M12, and with (B) HBsAg-specific IgG1, and (C) HbsAg-specific antibody binding to 1001 FcγR3A (CD16) expression determined by antibody subclass and Fc receptor binding assays using serum 1002 samples from pre-vaccinated individuals. Spearman correlation and t-test were used to evaluate for the 1003 significance of the correlation. *coef* (regression coefficient). t (t-statistic). $P \le 0.05$ was considered 1004 significant. (Shape: triangle-Male, circle-Female; color: grey- non-infected, black- low CAA, blue- high 1005 CAA).

¹⁰⁰⁷**Fig 9. Lower levels of cytokines/chemokines important in the activation and maturation of innate** ¹⁰⁰⁸**immune cells in** *S. mansoni***-infected individuals pre-vaccination and day 12 post-vaccination.** (A) 1009 CXCL10 levels pre-vaccination (D0) non-infected, n =19, low CAA, n =31, and high CAA, n =25, and 1010 (B) CCL19, (C) CCL26, (D) CCL27, (E) IL-1 β , and (F) IL-10 levels at D12 post vaccination non-1011 infected, $n = 15$, low CAA, $n = 26$, and high CAA, $n = 23$], in the culture supernatant of PBMCs stimulated 1012 for 18 hours with CLO97 (TLR7/8 agonist) or untreated (UNT). Data shown as \pm SEM. * P \leq 0.05 1013 Wilcoxon matched-pairs signed rank test performed on UNT vs. CLO97 or each non-infected, or low ¹⁰¹⁴CAA, or high CAA, and within the CLO97-treated group a Wilcoxon rank-sum test on non-infected vs. 1015 low CAA, or non-infected vs. high CAA, or low CAA vs. high CAA. Non-infected- light grey, low CAA 1016 - blue, and high CAA - dark grey.

¹⁰¹⁸**Supporting information captions**

¹⁰¹⁹**S1 Fig. Elevated plasma cytokines/chemokines in** *S. mansoni***-infected individuals pre-vaccination.**

1020 (A) CCL7, (B) CCL11, (C) CCL22, (D) CCL24, (E) IL-2, and (F) M-CSF levels in the plasma of non-

1021 infected, $n = 19$, low CAA, $n = 32$, and high CAA, $n = 24$, individuals pre-vaccination (day 0). Data 1022 shown as \pm SEM. * P \leq 0.05. Wilcoxon rank-sum test performed on non-infected vs low CAA, or non-1023 infected vs high CAA, or low CAA vs high CAA for each time point separately. Non-infected- light grey, 1024 low CAA - blue, and high CAA - dark grey. ¹⁰²⁶**S2 Fig. CCL17 and soluble IL-2R levels in individuals with** *S. mansoni* **infection correlate with** ¹⁰²⁷**Hepatitis B titers post-vaccination.** Scatter plots of Hepatitis B titers at M12 as a function of (A-B)

¹⁰²⁸CCL17 and (D-E) soluble IL-2R cytokine levels in the plasma of non-infected participants at D0, n =19,

1029 low CAA, $n = 32$, and high CAA, $n = 24$, and M12 post-vaccination, $n = 15$, low CAA, $n = 29$, and high

1030 CAA, $n = 19$, $P \le 0.05$. Linear regressions were fit between Hepatitis B titers and the cytokines adjusted

1031 for sex and student t-tests were used to evaluate for the significance of the association. t (t-statistic). $P \leq$ 1032 0.05 was considered significant. (Shape: circle-females, triangle-males; color: grey- non-infected, black-

1033 low CAA, blue- high CAA). (C) Soluble IL-2R levels in the plasma of non-infected individuals pre-

1034 vaccination (D0), n =19, low CAA, n =32, and high CAA, n =24, and M12 post-vaccination, n =15, low

1035 CAA, $n = 29$, and high CAA, $n = 19$. Non-infected- light grey, low CAA - blue, and high CAA - dark grey.

1036

1037 **S3 Fig. Flow cytometry gating strategy for T cell populations.** Representative plots showing non-1038 circulating T follicular helper cells (cTfh) populations as CD3⁺CD45RA-CD25 CXCR5 and cTfh 1039 populations as CD3⁺CD45RA⁻CD25⁻CXCR5⁺, identifying cTfh1 as CXCR3⁺, cTfh2 as CXCR3⁻ 1040 CCR6, and cTfh17 as CXCR3 CCR6⁺. Regulatory T cells (Tregs) were identified as 1041 CD3⁺CD4⁺CD45RA⁻CD127⁻CD25⁺Foxp3⁺.

¹⁰⁴³**S4 Fig. Flow cytometry gating strategy for B cell populations.** Representative plots showing activated 1044 B cells (ABC) as CD19⁺CD10IgD⁻CD71⁺CD38⁻CD20⁺ and antibody secreting B cells (ASC) as 1045 CD19⁺CD10TgD⁻CD71⁺CD38⁺CD20⁻

1046

1047 **S5 Fig. Frequencies of Activated B cells (ABC) were elevated in** *S. mansoni* **infection pre- and post-1048** vaccination. Frequencies of (A) ABCs [CD19⁺CD10^TgD⁻CD71⁺CD38⁻CD20⁺], and (B) IgG⁺ ABCs, 1049 were identified by flow cytometry of PBMCs from individuals pre-vaccination (D0) non-infected, $n = 16$, 1050 low CAA, $n = 29$, and high CAA, $n = 24$], M7 post-vaccination non-infected, $n = 14$, low CAA, $n = 17$, 1051 and high CAA, $n = 20$, and M12 post-vaccination non-infected, $n = 16$, low CAA, $n = 23$, and high CAA, 1052 n = 21. Data shown as \pm SEM. * P \leq 0.05. Wilcoxon rank-sum test performed on non-infected vs low ¹⁰⁵³CAA, or non-infected vs high CAA, or low CAA vs high CAA for each time point separately D0, M7, or ¹⁰⁵⁴M12. Non-infected- light grey, low CAA - blue, and high CAA - dark grey. (C) Linear regressions were 1055 fit between Hepatitis B titers and IgA^+ ASCs adjusted for sex and student t-tests were used to evaluate for 1056 the significance of the association. t (t-statistic). $P \le 0.05$ was considered significant. (Shape: triangle-1057 Male, circle-Female; color: grey- non-infected, black- low CAA, blue- high CAA).

¹⁰⁵⁹**S6 Fig. Plasma IgE is elevated pre-vaccination and remains elevated at month 12 post-vaccination** ¹⁰⁶⁰**in** *S. mansoni***-infected individuals.** Plasma IgE levels pre-vaccination (D0) and M12 post-vaccination. 1061 D0 non-infected, $n = 17$, low CAA, $n = 20$, and high CAA, $n = 19$, and M12 post-vaccination non-1062 infected, n = 15, low CAA, n = 26, and high CAA, n = 20. Data shown as \pm SEM. * P \leq 0.05. Wilcoxon 1063 rank-sum test performed on non-infected vs low CAA, or non-infected vs high CAA, or low CAA vs high ¹⁰⁶⁴CAA for each time point separately D0, or M12. Non-infected- light grey, low CAA - blue, and high 1065 CAA - dark grey.

1067 **S7 Fig. Flow cytometry gating strategy for monocyte populations.** Representative plots showing non-1068 classical (NC) monocytes as CD3CD19CD14^{dim}CD16⁺, classical monocytes (CL) as CD3CD19⁻ 1069 CD14⁺CD16⁺, and intermediate monocytes (INT) as CD3 CD19 CD14⁺CD16.

¹⁰⁷¹**S8 Fig. Flow cytometry gating strategy for monocyte populations.** Frequencies of monocyte 1072 populations (A) (classical [CD3CD19-CD14⁺CD16], (B) intermediate [CD3CD19⁻CD14⁺CD16⁺], and

1099

¹¹⁰⁰**S9 Table.** Ex vivo B cell staining panel for PBMCs.

1101

1102 **S10 Table.** T cell staining panel for PBMCs after Hepatitis B peptide stimulation.

 $\,$ D

D

в

%cTfh2 (%CD3+CD4+)

 $\mathsf E$

 $8-$

O

 $\boldsymbol{\mathsf{A}}$

CAA Groups

D